1. Home
  2. KDLY vs NXTC Comparison

KDLY vs NXTC Comparison

Compare KDLY & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KDLY
  • NXTC
  • Stock Information
  • Founded
  • KDLY 2019
  • NXTC 2015
  • Country
  • KDLY United States
  • NXTC United States
  • Employees
  • KDLY N/A
  • NXTC N/A
  • Industry
  • KDLY
  • NXTC Biotechnology: Pharmaceutical Preparations
  • Sector
  • KDLY
  • NXTC Health Care
  • Exchange
  • KDLY NYSE
  • NXTC Nasdaq
  • Market Cap
  • KDLY 10.9M
  • NXTC 9.3M
  • IPO Year
  • KDLY 2024
  • NXTC 2019
  • Fundamental
  • Price
  • KDLY $13.86
  • NXTC $0.41
  • Analyst Decision
  • KDLY
  • NXTC Strong Buy
  • Analyst Count
  • KDLY 0
  • NXTC 2
  • Target Price
  • KDLY N/A
  • NXTC $3.50
  • AVG Volume (30 Days)
  • KDLY 5.3M
  • NXTC 178.3K
  • Earning Date
  • KDLY 05-08-2025
  • NXTC 05-01-2025
  • Dividend Yield
  • KDLY N/A
  • NXTC N/A
  • EPS Growth
  • KDLY N/A
  • NXTC N/A
  • EPS
  • KDLY N/A
  • NXTC N/A
  • Revenue
  • KDLY $2,470,466.00
  • NXTC N/A
  • Revenue This Year
  • KDLY N/A
  • NXTC N/A
  • Revenue Next Year
  • KDLY N/A
  • NXTC N/A
  • P/E Ratio
  • KDLY N/A
  • NXTC N/A
  • Revenue Growth
  • KDLY N/A
  • NXTC N/A
  • 52 Week Low
  • KDLY $0.65
  • NXTC $0.22
  • 52 Week High
  • KDLY $5.25
  • NXTC $1.82
  • Technical
  • Relative Strength Index (RSI)
  • KDLY N/A
  • NXTC 45.41
  • Support Level
  • KDLY N/A
  • NXTC $0.34
  • Resistance Level
  • KDLY N/A
  • NXTC $0.47
  • Average True Range (ATR)
  • KDLY 0.00
  • NXTC 0.06
  • MACD
  • KDLY 0.00
  • NXTC 0.01
  • Stochastic Oscillator
  • KDLY 0.00
  • NXTC 39.66

About KDLY KINDLY MD INC

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: